Aradigm says U.K. Dstl receives funding of up to $6.9M from DTRA
Aradigm said that the U.K. Defence Science and Technology Laboratory have received funding of up to $6.9 million from the U.S. Defense Threat Reduction Agency for a program entitled "Inhalational ciprofloxacin for improved protection against biowarfare agents". The inhalational ciprofloxacin formulations used in this program are Aradigm's proprietary investigational drugs Pulmaquin and Lipoquin. The total potential funding provided to Dstl is $3.2M for the base period and $3.7M for the option period. The initial funding released is $1.7M. Dstl, in conjunction with its key sub-contractors including Aradigm Corporation, will conduct research relating to the efficacy of Pulmaquin and Lipoquin in animal models of Francisella tularensis, Burkholderia pseudomallei, Burkholderia mallei and Coxiella burnetii.